Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0023 | 0.0535 | 0.0739 |
Schistosoma mansoni | hypothetical protein | 0.0034 | 0.2617 | 0.3318 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.5463 | 0.5833 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0023 | 0.0535 | 0.0739 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0023 | 0.0535 | 0.0679 |
Schistosoma mansoni | hypothetical protein | 0.0021 | 0.0191 | 0.0242 |
Schistosoma mansoni | bromodomain containing protein | 0.0064 | 0.7886 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.005 | 0.5463 | 0.4979 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.005 | 0.5463 | 0.4979 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.2617 | 0.2684 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.005 | 0.5463 | 0.5833 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.006 | 0.724 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.4163 | 0.4395 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.9228 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.3391 | 0.3541 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0036 | 0.2951 | 0.4076 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0036 | 0.2951 | 0.4076 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0034 | 0.2617 | 0.183 |
Brugia malayi | Bromodomain containing protein | 0.0039 | 0.3378 | 0.2673 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.3818 | 0.4014 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.006 | 0.724 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Effect (functional) | = 27.4 mg 100g-1 | Anti-uterotrophic effect in mice at 5 ug | ChEMBL. | 3941415 |
Effect (functional) | = 27.4 mg 100g-1 | Anti-uterotrophic effect in mice at 5 ug | ChEMBL. | 3941415 |
Effect (functional) | = 33.8 mg 100g-1 | Anti-uterotrophic effect in mice at 1.0 ug | ChEMBL. | 3941415 |
Effect (functional) | = 33.8 mg 100g-1 | Anti-uterotrophic effect in mice at 1.0 ug | ChEMBL. | 3941415 |
Effect (functional) | = 40.4 mg 100g-1 | Anti-uterotrophic effect in mice at 25 ug | ChEMBL. | 3941415 |
Effect (functional) | = 40.4 mg 100g-1 | Anti-uterotrophic effect in mice at 25 ug | ChEMBL. | 3941415 |
Effect (functional) | = 41.3 mg 100g-1 | Anti-uterotrophic effect in mice at 100 ug | ChEMBL. | 3941415 |
Effect (functional) | = 41.3 mg 100g-1 | Anti-uterotrophic effect in mice at 100 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 5 % | Anti-uterotrophic effect in immature mice at 100 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 5 % | Anti-uterotrophic effect in immature mice at 100 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 8 % | Anti-uterotrophic effect in immature mice at 25 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 8 % | Anti-uterotrophic effect in immature mice at 25 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 31 % | Anti-uterotrophic effect in immature mice at 1.0 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 31 % | Anti-uterotrophic effect in immature mice at 1.0 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 54 % | Anti-uterotrophic effect in immature mice at 5 ug | ChEMBL. | 3941415 |
Inhibition (functional) | = 54 % | Anti-uterotrophic effect in immature mice at 5 ug | ChEMBL. | 3941415 |
RBA (binding) | = 1 % | Inhibition of [3H]-estradiol binding to calf uterine estrogen receptor | ChEMBL. | 3941415 |
RBA (binding) | = 1 % | Inhibition of [3H]-estradiol binding to calf uterine estrogen receptor | ChEMBL. | 3941415 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.